Sex hormones, gonadotropins and prolactin in male epileptic subjects in remission: role of the epileptic syndrome and of antiepileptic drugs.
Sex steroid peripheral pattern, pulsatile luteinizing hormone (LH) secretion, gonadotropin and prolactin responses to LH-releasing hormone (LHRH) and thyrotropin-releasing hormone (TRH) were studied in 35 male epileptics treated with phenobarbital (PB), carbamazepine (CBZ), or phenytoin (PHT), and in age-matched healthy males. Idiopathic generalized epilepsy (IGE) was diagnosed in 12 cases and partial epilepsy (PE) in 23 cases. Patients were seizure-free and did not show EEG abnormalities at repeated controls in the last 5 years, so that interfering effects of seizures were possibly excluded. The aim of the study was to evaluate both the role of epileptic syndromes and of anti-epileptic drugs on the endocrine function. Changes in sex hormone binding globulin, total and free testosterone, dihydrotestosterone and delta 4-androstenedione were found to be independent of the epileptic syndrome type. The LH response to LHRH was lower in PB-treated PE than in IGE subjects on the same drug regimen. An impairment of LH pulsatility with respect to controls was found in PE but not in IGE patients taking PB. Among antiepileptic drugs, PHT is associated with higher sex hormone binding globulin and estradiol and lower free testosterone and dihydrotestosterone levels. PB and CBZ, but not PHT, blunt the LH response to exogenous LHRH in PE. Prolactin responses to TRH were consistently enhanced in PE subjects treated with CBZ or PHT.
Murialdo
G
G
Department of Endocrinological and Metabolic Sciences, University of Genoa, Italy.
Galimberti
C A
CA
Fonzi
S
S
Manni
R
R
Costelli
P
P
Parodi
C
C
Torre
F
F
Solinas
G P
GP
Polleri
A
A
Tartara
A
A
D000328:Adult; D000735:Androstenedione / Q000097:blood; D000927:Anticonvulsants / Q000627:therapeutic use*; D002220:Carbamazepine / Q000627:therapeutic use; D013196:Dihydrotestosterone / Q000097:blood; D004828:Epilepsies, Partial / Q000097:blood / Q000188:drug therapy*; D004829:Epilepsy, Generalized / Q000097:blood / Q000188:drug therapy*; D004958:Estradiol / Q000097:blood; D005640:Follicle Stimulating Hormone / Q000097:blood*; D012739:Gonadal Steroid Hormones / Q000097:blood*; D007987:Gonadotropin-Releasing Hormone; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D011388:Prolactin / Q000097:blood*; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013739:Testosterone / Q000097:blood; D013973:Thyrotropin-Releasing Hormone
D000927:Anticonvulsants; D012739:Gonadal Steroid Hormones; D012738:Sex Hormone-Binding Globulin; D013196:Dihydrotestosterone; D007987:Gonadotropin-Releasing Hormone; D002220:Carbamazepine; D013739:Testosterone; D000735:Androstenedione; D004958:Estradiol; D013973:Thyrotropin-Releasing Hormone; D010672:Phenytoin; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D010634:Phenobarbital